These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35950872)

  • 1. Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
    Kalogeropulou AF; Purlyte E; Tonelli F; Lange SM; Wightman M; Prescott AR; Padmanabhan S; Sammler E; Alessi DR
    Biochem J; 2022 Sep; 479(17):1759-1783. PubMed ID: 35950872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease.
    Tezuka T; Ishiguro M; Taniguchi D; Osogaguchi E; Shiba-Fukushima K; Ogata J; Ishii R; Ikeda A; Li Y; Yoshino H; Matsui T; Kaida K; Funayama M; Nishioka K; Kumazawa F; Matsubara T; Tsuda H; Saito Y; Murayama S; Imai Y; Hattori N
    Neurobiol Dis; 2024 Sep; 199():106571. PubMed ID: 38901781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.
    Fan Y; Nirujogi RS; Garrido A; Ruiz-Martínez J; Bergareche-Yarza A; Mondragón-Rezola E; Vinagre-Aragón A; Croitoru I; Gorostidi Pagola A; Paternain Markinez L; Alcalay R; Hickman RA; Düring J; Gomes S; Pratuseviciute N; Padmanabhan S; Valldeoriola F; Pérez Sisqués L; Malagelada C; Ximelis T; Molina Porcel L; Martí MJ; Tolosa E; Alessi DR; Sammler EM
    Acta Neuropathol; 2021 Sep; 142(3):475-494. PubMed ID: 34125248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
    Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
    Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review.
    Simpson C; Vinikoor-Imler L; Nassan FL; Shirvan J; Lally C; Dam T; Maserejian N
    Parkinsonism Relat Disord; 2022 May; 98():103-113. PubMed ID: 35654702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
    Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
    PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of phospho-specific Rab protein antibodies to monitor
    Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR
    Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
    Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
    Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
    Rudenko IN; Cookson MR
    Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes.
    Wang X; Bondar VV; Davis OB; Maloney MT; Agam M; Chin MY; Cheuk-Nga Ho A; Ghosh R; Leto DE; Joy D; Calvert MEK; Lewcock JW; Di Paolo G; Thorne RG; Sweeney ZK; Henry AG
    Elife; 2023 Oct; 12():. PubMed ID: 37874617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.